Oxidative Medicine and Cellular Longevity · 2020 · 65 citations · 25 references
MedicineMolecular MedicineOncologyCancer GeneticsMolecular OncologyTranscriptomicsBiomarker ValidationCancer BiomarkersCancer GenomicsCancer TranscriptomicsMolecular Tumor ProfilingRenal Cell CarcinomaCalibration CurvesCox RegressionLong Noncoding Rna ProfilingNoncoding Rna Biomarker DiscoveryNoncoding Rna Expression ProfilingPrognostic Expression SignaturesPrognostic Rna BiomarkersRenal Cell Carcinoma Biomarkers
BACKGROUND: Redox plays an essential role in the pathogeneses and progression of tumors, which could be regulated by long noncoding RNA (lncRNA). We aimed to develop and verify a novel redox-related lncRNA-based prognostic signature for clear cell renal cell carcinoma (ccRCC). MATERIALS AND METHODS: A total of 530 ccRCC patients from The Cancer Genome Atlas (TCGA) were included in this study. All the samples were randomly split into training and test group at a 1 : 1 ratio. Then, we screened differentially expressed redox-related lncRNAs and constructed a novel prognostic signature from the training group using the least absolute shrinkage and selection operation (LASSO) and COX regression. Next, to verify the accuracy of the signature, we conducted risk and survival analysis, as well as the construction of ROC curve, nomogram, and calibration curves in the training group, test group, and all samples. Finally, the redox gene-redox-related lncRNA interaction network was constructed, and gene set enrichment analysis (GSEA) was performed to investigate the status of redox-related functions between high/low-risk groups. RESULTS: was significantly associated with overall survival in ccRCC patients. The signature proved efficient, and thus, a nomogram was successfully assembled. In addition, the GSEA results demonstrated that two major redox-related functions were enhanced in the high-risk group ccRCC patients. CONCLUSIONS: Our findings robustly demonstrate that the nine-redox-related lncRNA signature could serve as an efficient prognostic indicator for ccRCC.
25
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2020 · 21.4K citations · Full text
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Robert J. Motzer, Bernard Escudier, Saby George et al. · New England Journal of Medicine · 2015 · 5.9K citations · Full text
Medicine, Oncology, Pharmacotherapy +17
Comprehensive molecular characterization of clear cell renal cell carcinoma